Human Monocytes - CD14, CD16 - Ziegler-Heitbrock


Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis


Background: We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET). Methods and Results: We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(−); n=15), and analyzed 3 distinct monocyte subsets (CD14+CD16−, CD14++CD16+, and CD14+−CD16+). Monocyte subsets were also analyzed in 10 Rx(−) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+ monocytes in Rx(+) patients (10.8 [0.2–23.5] %) was significantly lower than in Rx(−) patients (23.0 [11.5–38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14–0.62] to 0.17 [0.04–0.43] (P=0.017). The proportion of CD14++16+ monocytes showed a significant decrease from 22.2 [8.8–38.4] % to 8.4 [1.8–16.8] % (P=0.001). The decrease in the proportion of CD14++16+ monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027). Conclusions: CD14++16+

Authors: Orii M, Imanishi T, Teraguchi I, Nishiguchi T, Shiono Y, Yamano T, Ino Y, Hirata K, Kubo T, Tanaka A, Akasaka T.
Journal: Circ J. ;79:1585-92
Year: 2015
PubMed: Find in PubMed